Dr. Martens Regulatory News (DOCS)

1 July 2026

Dr. Martens plc

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

AND COMMITTEE CHANGES

Dr. Martens plc ('Dr. Martens' or 'the Company') is pleased to announce the appointment of Melanie Richards CBE as an Independent Non-Executive Director of the Company, with effect from the conclusion of the Company's Annual General Meeting on 15 July 2026 ('the 2026 AGM'). This follows the Company's prior announcement on 27 May 2026 that Lynne Weedall would step down from the Board following the 2026 AGM and that a further update on Board succession would be made in due course.

Melanie is former Deputy Chair of KPMG UK and currently serves as Chair of Azets and as a Non-Executive Director of Morgan Stanley & Co. International and HKA Global. She brings broad-based executive, commercial, financial and capital markets experience, together with significant board and advisory experience and a strong track record of contributing to strategic direction and commercial performance in complex organisations.

Upon joining the Board, Melanie will be appointed Senior Independent Director and Chair of the Nomination Committee, and will also become a member of the Audit and Risk Committee and the Remuneration Committee, while Andrew Harrison, Independent Non-Executive Director, will be appointed Chair of the Remuneration Committee. These appointments will take effect from the conclusion of the 2026 AGM.

Paul Mason, Chairman, said: 'We are delighted to welcome Melanie to the Board. Her extensive board experience, together with her valuable financial and commercial insight and fresh perspective, will strengthen the Board as we continue to execute our consumer-first strategy and deliver long-term sustainable growth. We are pleased that Andrew brings both continuity and experience, as he becomes Chair of the Remuneration Committee'.

NOTES

1. This announcement is made pursuant to UK Listing Rule 6.4.6R.

2. The Company confirms that there is no further information that is required to be disclosed pursuant to UK Listing Rule 6.4.8R.

About Dr. Martens

Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot - named after the date it was produced - rolled off the production line on 1st April 1960. Originally chosen by workers for their air-cushioned comfort and durability, "Docs" or "DM's" were later adopted by musicians and subcultural pioneers who took them from the street to the global stage.

Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,700 people. The company continues to honour the brand's heritage through its 'Made in England' footwear, manufactured at its original Northamptonshire factory, while meeting global demand from multiple high-quality production sites across Asia. All our products are made with an unwavering commitment to craft, combined with innovative techniques.

A brand built to put a bounce in the step of those who stand out from the crowd, Dr. Martens is available through Direct-to-Consumer (Retail and Ecommerce) and Wholesale channels. The brand's collections range from its Original silhouettes - The Icons such as the 1460 boot, 1461 shoe, 2976 Chelsea boot, and Adrian loafer - to modern franchises like the Zebzag, Buzz, and Lowell. The lineup also includes an extensive range of sandals, a dedicated Kids collection, and a curated selection of bags, small leather goods, and accessories.

Every Dr. Martens collection reflects craftsmanship, heritage, timeless style, comfort, and versatility. Having transcended generations, the brand stays as relevant today as it was at its inception. Its signature yellow welt stitching, grooved sole edges, and scripted "With Bouncing Soles" heel loops remain iconic symbols recognised around the world.

Dr. Martens plc (DOCS.L) is listed on the main market of the London Stock Exchange and is a constituent of the FTSE 250 index.

For more information, visit www.drmartens.com or www.drmartensplc.com